Skip to content

Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut

Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06009250
Enrollment
200
Registered
2023-08-24
Start date
2023-12-31
Completion date
2024-12-31
Last updated
2023-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD, NAFLD

Brief summary

The goal of this observational study is to detect the prevalence of NAFLD in CKD patients The main question\[s\] it aims to answer are: * \[question 1\] prevalence of NAFLD in CKD patients. * \[question 2\] the relationship between NAFLD and CKD.

Detailed description

The goal of this observational study is to detect the prevalence of NAFLD in CKD patients The main question\[s\] it aims to answer are: * \[question 1\] prevalence of NAFLD in CKD patients. * \[question 2\] the relationship between NAFLD and CKD.

Interventions

None listed

Sponsors

Muhammad Ameen Abdelrady Abdelaziz
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

* CKD patients

Exclusion criteria

* HCV and HBV Positive patients * Alcoholics * patient on Hemodialysis * patients with wilson disease * patients with alpha one antitrypsin deficiency

Design outcomes

Primary

MeasureTime frameDescription
Complete Blood Picture (WBCs, HB, Patelets1 yeartotal leucocytic count Hemoglobin level and platelet count will be assessed in our patients and will be reported in a table
BUN, Cr level and estimated GFR1 yearparticipants will be assessed regarding BUN, CR and estimated GFR to confirm and follow up CKD patients involved in the study.
Lipid Profile1 yearparticipants will be assessed regarding Cholesterol level, Triglycerides, HDL and LDL. results will be reported in a table
abdominal ultrasound1 yearassessment of Liver regarding fatty liver disease by Ultrasound.
serum Uric Acid1 yearserum uric acid will be assessed and reported in our patients
liver enzymes1 yearparticipants will undergo assessment of liver enzymes (AST and ALT) and results will be reporeted in a table.
Fibroscan1 yearparticipants will undergo fibroscanning of the liver to assess NAFLD and results will be reported in a table.

Secondary

MeasureTime frameDescription
Body Mass Index1 yearBMI will also be calculated.
Waist Circumference1 yearwaist circumference measurement.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026